Lansforsakringar Fondforvaltning Ab (Publ) Vertex Pharmaceuticals Inc Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $15.9 Billion
- Q1 2025
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 136,311 shares of VRTX stock, worth $60.1 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
136,311
Previous 144,708
5.8%
Holding current value
$60.1 Million
Previous $58.3 Million
13.41%
% of portfolio
0.42%
Previous 0.34%
Shares
2 transactions
Others Institutions Holding VRTX
# of Institutions
1,833Shares Held
233MCall Options Held
1.38MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.5MShares$12.6 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$10.4 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.4 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$6.41 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.2 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $113B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...